ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced financial results for the quarter ended September 30, 2013.
For the three months ended September 30, 2013, the Company incurred a net loss of $3.8 million, or $0.07 per basic and diluted share, compared to a net loss of $600,000, or $0.02 per basic and diluted share during the quarter ended September 30, 2012.
Help employers find you! Check out all the jobs and post your resume.
